Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

Filip Janku,Ulka N. Vaishampayan,Vivek Khemka,Minny Bhatty,Eric J. Sherman,Jessica J. Tao,Jonathan Whisenant,David S. Hong,Nam Bui,Shivaani Kummar,Lynn G. Feun,Aparna Raj Parikh,Chao Zhang,Glenn Michelson,Eric Martin,Rafe Shellooe,Paul Severson,Michael Pelayo,David A. Karlin,Sunil Sharma

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

2018

2583Background: First-generation BRAF inhibitors (BRAFi) show high response rates and prolonged survival in some BRAFV600-mutant cancers; however, paradoxical activation of the RAF/MEK/ERK pathway ...

Keywords:

Precision medicine
Pathology
BRAF Inhibitor PLX8394
Oncology
Internal medicine
Medicine
Cancer research
MAPK/ERK pathway

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations